Paper17526555
High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
Syversen SW and 8 others. Ann Rheum Dis, 2008. Cited by 243 papers, by iCite.
Cite this record
ConductScience Library. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Papers, record 17526555. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17526555
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arthritis, Rheumatoid | Major topic |
| Peptides, Cyclic | Major topic |
| Algorithms | |
| Antirheumatic Agents | |
| Autoantibodies | |
| Biomarkers | |
| Cohort Studies | |
| Disease Progression | |
| Female | |
| Humans | |
| Immunoglobulin A | |
| Immunoglobulin G | |
| Longitudinal Studies | |
| Male | |
| Middle Aged | |
| Odds Ratio | |
| Predictive Value of Tests | |
| Radiography | |
| Rheumatoid Factor | |
| Sex Factors |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03265236 | Diagnostic Value of Anti-MCV in Pts With RA | Background |
Source ClinicalTrials.gov
Cited by115
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 243 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42836514 | Temporal Patterns of Outcomes After DMARD Tapering or Withdrawal in Rheumatoid Arthritis With Sustained Disease Control: A Systematic Review and Meta-Analysis. | Clin Transl Sci | 2026 | https://conductscience.org/library/papers/42836514 | PubMed |
| 42192467 | Radiographic outcome over 15 years in patients with early rheumatoid arthritis - a BARFOT-study. | BMC Rheumatol | 2026 | https://conductscience.org/library/papers/42192467 | PubMed |
| 42134050 | Aggressive Seropositive Rheumatoid Arthritis With Diffuse Osteolytic Bone Lesions, Hypercalcemia, and Lymphadenopathy Masquerading as Hematologic Malignancy: A Case Report. | J Investig Med High Impact Case Rep | 2026 | https://conductscience.org/library/papers/42134050 | PubMed |
| 41095913 | Structural and Functional Outcomes in Rheumatoid Arthritis After 10-Year Therapy with Disease-Modifying Antirheumatic Drugs Under Tight Control: Evidence from Real-World Cohort Data. | J Clin Med | 2025 | https://conductscience.org/library/papers/41095913 | PubMed |
| 40757796 | Abnormal Ulnar Variance: A New Perspective in Rheumatoid Arthritis-Related Joint Damage. | Arch Rheumatol | 2025 | https://conductscience.org/library/papers/40757796 | PubMed |
| 40670424 | Polygenic risk scores of rheumatoid arthritis associated with seropositivity and bone erosions in a Taiwanese population. | Sci Rep | 2025 | https://conductscience.org/library/papers/40670424 | PubMed |
| 40204305 | Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study. | BMJ Open | 2025 | https://conductscience.org/library/papers/40204305 | PubMed |
| 40091354 | Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis. | Innate Immun | 2025 | https://conductscience.org/library/papers/40091354 | PubMed |
| 38843126 | Differences in referral path, clinical and radiographic outcomes between seronegative and seropositive rheumatoid arthritis Mexican Mestizo patients: A cohort study. | PLoS One | 2024 | https://conductscience.org/library/papers/38843126 | PubMed |
| 37809106 | Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion. | Front Immunol | 2023 | https://conductscience.org/library/papers/37809106 | PubMed |
| 37475973 | Clinical Implications of Shared Epitope and Anti-citrullinated Peptide Antibody in Patients With Rheumatoid Arthritis. | J Rheum Dis | 2022 | https://conductscience.org/library/papers/37475973 | PubMed |
| 37362488 | Association of the Clinical and Radiographic Findings at Onset With Future Joint Destruction in Patients With Rheumatoid Arthritis. | Cureus | 2023 | https://conductscience.org/library/papers/37362488 | PubMed |
| 36581910 | Erosion-free rheumatoid arthritis: clinical and conceptional implications-a BARFOT study. | BMC Rheumatol | 2022 | https://conductscience.org/library/papers/36581910 | PubMed |
| 36425102 | Inflammatory profile of incident cases of late-onset compared with young-onset rheumatoid arthritis: A nested cohort study. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/36425102 | PubMed |
| 36165675 | Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids. | Rheumatology (Oxford) | 2023 | https://conductscience.org/library/papers/36165675 | PubMed |
| 35885675 | Anti-Citrullinated Protein Antibody Titers Are Independently Modulated by Both Disease Activity and Conventional or Biologic Anti-Rheumatic Drugs. | Diagnostics (Basel) | 2022 | https://conductscience.org/library/papers/35885675 | PubMed |
| 35270012 | Inflammation and Bone Metabolism in Rheumatoid Arthritis: Molecular Mechanisms of Joint Destruction and Pharmacological Treatments. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35270012 | PubMed |
| 34980246 | Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution. | Arthritis Res Ther | 2022 | https://conductscience.org/library/papers/34980246 | PubMed |
| 34964030 | A not-to-miss Cause of Severe Cervical Spine Pain in a Patient with Rheumatoid Arthritis: A Case-Based Review. | Mediterr J Rheumatol | 2021 | https://conductscience.org/library/papers/34964030 | PubMed |
| 34671034 | Augmenting MNK1/2 activation by c-FMS proteolysis promotes osteoclastogenesis and arthritic bone erosion. | Bone Res | 2021 | https://conductscience.org/library/papers/34671034 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17526555
GET https://conductscience.org/api/papers/v1/17526555/cited_by?page=2